

IRISH MEDICINES BOARD ACTS 1995 AND 2006

MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007

(S.I. No.540 of 2007)

PA0973/001/001

Case No: 2067720

The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to

Sanofi Pasteur MSD S.p.A.

Via degli Aldobrandeschi, 15, 1-00163 Roma, Italy

an authorisation, subject to the provisions of the said Regulations, in respect of the product

ADDIFLU Suspension for Injection in pre-filled syringe. Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59C. 1 (2009/2010 Season)

The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document.

This authorisation, unless previously revoked, shall continue in force from **20/08/2009** until **07/06/2010**.

Signed on behalf of the Irish Medicines Board this

A person authorised in that behalf by the said Board.

Part II

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

ADDIFLU Suspension for Injection in pre-filled syringe Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59C.1
(2009/2010 Season).

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Influenza virus surface antigens (haemagglutinin and neuraminidase)*, of strains

A/Brisbane/59/2007 (H1N1) - like strain (A/Brisbane/59/2007, IVR-148)	15 micrograms**
--	-----------------

A/Brisbane/10/2007 (H3N2) - like strain (A/Uruguay/716/2007, NYMC X – 175C)	15 micrograms**
--	-----------------

B/Brisbane/60/2008 – like strain (B/Brisbane/60/2008)	15 micrograms**
---	-----------------

*propagated in eggs and adjuvanted with MF59C.1

**haemagglutinin

Adjuvant: MF59C.1 which is an exclusive adjuvant (Patent EP 0 399 843 B1): 9.75 mg squalene, 1.175 mg polysorbate 80, 1.175 mg sorbitan trioleate, 0.66 mg sodium citrate, 0.04 mg citric acid, water for injection.

For one dose of 0.5 ml

This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for the 2009/2010 season.

For excipients see section 6.1

3 PHARMACEUTICAL FORM

Suspension for injection in pre-filled syringe.

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

Active immunisation against influenza in the elderly (65 years of age and over), especially for those with an increased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).

4.2 Posology and method of administration

A single 0.5 ml dose should be administered by intramuscular injection into the deltoid muscle. Due to the presence of the adjuvant, the injection should be carried out by using a 1 inch needle.

4.3 Contraindications

Hypersensitivity to the active substances, to any of the excipients and to eggs, chicken proteins, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide (CTAB).

Immunisation shall be postponed in patients with febrile illness or acute infection.

4.4 Special warnings and precautions for use

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case a rare anaphylactic event occurs following the administration of the vaccine.

The vaccine Addiflu should under no circumstances be administered intravascularly or subcutaneously.

Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.

4.5 Interaction with other medicinal products and other forms of interaction

The vaccine may be given at the same time as other vaccines. Immunisation should be carried out on separate limbs. It should be noted that the adverse reactions may be intensified.

The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.

Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, hepatitis C and, especially HTLV1 have been observed. The Western Blot technique disproves the results. The transient false positive reactions could be due to the IgM response by the vaccine.

4.6 Pregnancy and lactation

Not applicable.

4.7 Effects on ability to drive and use machines

The vaccine is unlikely to produce any effect on the ability to drive and use machines.

4.8 Undesirable effects

A higher incidence of mild post-immunisation reactions has been reported with Addiflu compared to non-adjuvanted influenza vaccines.

Adverse reactions from clinical trials.

The safety of Addiflu is assessed in open label, uncontrolled clinical trials performed as annual update requirement, including at least 50 elderly aged 65 years or older. Safety evaluation is performed during the first 3 days following vaccination.

Undesirable effects reported are listed according to the following frequency.

Adverse events from clinical trials:

Common (>1/100, <1/10):

Local reactions: redness, swelling, pain at the injection site, ecchymosis, induration.

Systemic reactions: fever, malaise, shivering, fatigue, headache, sweating, myalgia, arthralgia.

These reactions usually disappear within 1-2 days without treatment.

From Post-marketing surveillance additionally, the following adverse events have been reported:

Uncommon (>1/1,000, <1/100):

Generalised skin reactions including pruritus, urticaria or non-specific rash.

Rare (>1/10,000, <1/1,000):

Neuralgia, paraesthesia, convulsions, transient thrombocytopenia.

Allergic reactions, in rare cases leading to shock, have been reported.

Very rare (<1/10,000):

Vasculitis with transient renal involvement and exudative erythema multiforme. Neurological disorders such as encephalomyelitis, neuritis and Guillain Barré syndrome.

4.9 Overdose

Overdosage is unlikely to have any untoward effect.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Seroprotection is generally obtained within 2 to 3 weeks. The duration of post vaccination immunity to homologous strains or to strains closely related to the vaccine strains varies, but it is usually 6-12 months. Although comparative field efficacy trials have not been performed, the antibody response to Addiflu is increased when compared to the response to vaccines without adjuvant, and is most pronounced for B and A/H3N2 influenza antigens. This increased response is seen particularly in elderly subjects with low pre-immunisation titre and/or with underlying diseases (diabetes and cardiovascular and respiratory diseases) who are at increased risk of complications of influenza infection. A similar immunogenicity profile has been noted after a second and third immunisation with Addiflu. Significant antibody rises after immunisation with Addiflu have also been shown against heterovariant strains, antigenically different from those included in the vaccine.

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

Preclinical data reveal no special hazard for humans based on conventional studies of repeated-dose toxicity, genotoxicity and local tolerance.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Adjuvant: *see section 2, Qualitative and Quantitative composition.*

Other: sodium chloride, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, magnesium chloride hexahydrate, calcium chloride dihydrate and water for injections.

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf Life

1 year.

6.4 Special precautions for storage

Store in a refrigerator (2°C - 8°C). Do not freeze. Protect from light.

6.5 Nature and contents of container

0.5 ml of suspension for injection in pre-filled syringe (type I glass), presented with or without needle.

Pack of 1, with or without needle.

Pack of 10x, with or without needle.

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

The vaccine should be allowed to reach room temperature before use. The vaccine is a milky-white suspension. Gently shake before use.

7 MARKETING AUTHORISATION HOLDER

Sanofi Pasteur MSD S.p.A.,
Via Degli Aldobrandeschi 15,
1-00163 Rome,
Italy.

8 MARKETING AUTHORISATION NUMBER

PA 0973/001/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 01 September 2000

Date of last renewal: 08 June 2005

10 DATE OF REVISION OF THE TEXT

August 2009